Tuune Co-Founder, Shardi Nahavandi, is revolutionising Women’s Health by offering individualized hormonal analysis and birth control.
Tuune announced the closing of a $4.6M fundraising round led by venture capital firm Octopus Ventures and included the likes of Aureum.
Speaking of the investment, Anjel Noorbakhsh Ashman, Investment Manager Aureum said:
“Tuune was my first deal as an Angel for Ada Ventures but I couldn’t say much until now. It has been a pleasure to witness the tangible steps this company is making to improve the healthcare experience for women.”
It has been a pleasure to witness the tangible steps this company is making
Tuune’s mission is to solve problems that women face with their hormonal health. Through this focus they are on a mission to make female hormones a pillar of modern holistic healthcare and bridge the gaps in understanding of conditions like PCOS; endometriosis; and cardiometabolic, mental, and bone health.
Shardi Nahavandi, the co-founder of Tuune, explained how her founder story led her to this point:
“After being misdiagnosed with cancer and dismissed by many healthcare professionals, I knew I had to not only advocate for myself but for all women who are told that side effects are normal”
I knew I had to not only advocate for myself but for all women
The team will use the raise to launch in the U.S. market with a focus on developing a more individualised medical system that puts hormones first.
Peter Fish, Clinical Innovation Lead, reflected on the raise:
“It wouldn’t have been possible without the hard work of our team, especially my co-founder Shardi Nahavandi”
It wouldn’t have been possible without the hard work of our team
